Skip to content

Clinical trial assessing xenon therapy for panic attack patients

Xenon in the treatment of panic disorder: an open-label study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN15184285
Enrollment
90
Registered
2017-04-14
Start date
2014-02-01
Completion date
Unknown
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Panic attack disorder 2. Panic attack disorder combined with comorbidity psychiatric conditions Mental and Behavioural Disorders Panic attack disorder

Interventions

All patients undergo administration of a xenon-oxygen mixture via a face mask. Each patient in the study undergoes between 6 and 7 treatments with xenon-oxygen mixture. The first three sessions are ca

Sponsors

Nobilis Therapeutics
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of panic disorder (F41.0) according to ICD-10 2. Age 18-75 3. Willing to sign informed consent

Exclusion criteria

Exclusion criteria: 1. Known reactions to xenon therapy 2. Organ failure

Design outcomes

Primary

MeasureTime frame
Number of panic attacks are assessed through self-reporting throughout the study

Secondary

MeasureTime frame
1. Anxiety is measured by the “anxiety” subset of the Hospital Anxiety and Depression Scale (HADS_T) at baseline, 30 and 180 days 2. Severity of disease is assessed by Clinical Global Impression Scale Improvement Subscale (CGI-I) at baseline, 30 and 180 days 3. Symptom changes are quantified by the Zung Self-Rating Anxiety Scale (SAS) at baseline, 30 and 180 days 4. Depression is assessed by the “Depression” subset of the Hospital Anxiety and Depression Scale (HADS_T) at baseline, 30 and 180 days

Countries

Russian Federation

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 9, 2026